1

2

3

4

5
Boyle Robert George, Saxty Gordon, Verdonk Marinus Leendert, Taylor Richard David, Hamlett Christopher, Sore Hannah Fiona: Heterocyclic containing amines as kinase b inhibitors. Astex Therapeutics, The Institute Of Cancer Research Royal Cancer Hospital, Cancer Research Technology, Boyle Robert George, Saxty Gordon, Verdonk Marinus Leendert, Taylor Richard David, Hamlett Christopher, Sore Hannah Fiona, HUTCHINS Michael Richard, December 28, 2006: WO/2006/136823 (40 worldwide citation)

The invention provides a compound of the formula (I) or a salt, solvate, tautomer or N-oxide thereof; for use as a PKB kinase inhibitor or PKA kinase inhibitor. In formula (I), A is a saturated hydrocarbon linker group; E is a monocyclic or bicyclic carbocyclic or heterocyclic group; HET is a monocy ...


6
Berdini Valerio, Padova Alessandro, Saxty Gordon, Woolford Alison Jo Anne, Wyatt Paul Graham: (cdk) Inhibitors. Astex Technology, Berdini Valerio, Padova Alessandro, Saxty Gordon, Woolford Alison Jo Anne, Wyatt Paul Graham, HUTCHINS Michael Richard, February 19, 2004: WO/2004/014864 (34 worldwide citation)

The invention provides a compound of the formula (I) for use in the prophylaxis or treatment of a disease state or condition mediated by a cyclin dependent kinase: wherein A is a group R2 or CH2-R2 where R2 is a carbocyclic or heterocyclic group having from 3 to 12 ring members; B is a bond or an ac ...


7

8
Saxty Gordon, Verdonk Marinus Leendert, Caldwell John, Collins Ian, Cheung Kwai Ming, Da Fonseca, Mchardy Tatiana Faria: Pharmaceutical compounds. Astex Therapeutics, The Institute Of Cancer Reserarchroyal Cancer Hospital, Cancer Research Technology, Saxty Gordon, Verdonk Marinus Leendert, Caldwell John, Collins Ian, Cheung Kwai Ming, Da Fonseca, Mchardy Tatiana Faria, HUTCHINS Michael Richard, November 8, 2007: WO/2007/125320 (26 worldwide citation)

Compounds of the formula (I), and salts, solvates, tautomers and N-oxide thereof; wherein TG is selected from groups (1) and (2): wherein the asterisk (*) represents the point of attachment of the group E to the group X; Rla is an optionally substituted aryl or heteroaryl group; Rlb is hydrogen or a ...


9

10
SAXTY Gordon, MURRAY Christopher William, BERDINI Valerio, BESONG Gilbert Ebai, HAMLETT Christopher Charles Frederick, JOHNSON Christopher Norbert, WOODHEAD Steven John, READER Michael, REES David Charles, MEVELLEC Laurence Anne, ANGIBAUD Patrick René, FREYNE Eddy Jean Edgard, GOVAERTS Tom Cornelis Hortense, WEERTS Johan Erwin Edmond, PERERA Timothy Pietro Suren, GILISSEN Ronaldus Arnodus Hendrika Joseph, WROBLOWSKI Berthold, LACRAMPE Jean Fernand Armand, PAPANIKOS Alexandra, QUEROLLE Oliver Alexis Georges, PASQUIER Elisabeth Thérèse Jeanne, PILATTE Isabelle Noëlle Constance, BONNET Pascal Ghislain André, EMBRECHTS Werner Constant Johan, AKKARI Rhalid, MEERPOEL Lieven: Inhibiteurs de pyrazolyl-quinazoline kinase, Pyrazolyl quinazoline kinase inhibitors. Astex Therapeutics, SAXTY Gordon, MURRAY Christopher William, BERDINI Valerio, BESONG Gilbert Ebai, HAMLETT Christopher Charles Frederick, JOHNSON Christopher Norbert, WOODHEAD Steven John, READER Michael, REES David Charles, MEVELLEC Laurence Anne, ANGIBAUD Patrick René, FREYNE Eddy Jean Edgard, GOVAERTS Tom Cornelis Hortense, WEERTS Johan Erwin Edmond, PERERA Timothy Pietro Suren, GILISSEN Ronaldus Arnodus Hendrika Joseph, WROBLOWSKI Berthold, LACRAMPE Jean Fernand Armand, PAPANIKOS Alexandra, QUEROLLE Oliver Alexis Georges, PASQUIER Elisabeth Thérèse Jeanne, PILATTE Isabelle Noëlle Constance, BONNET Pascal Ghislain André, EMBRECHTS Werner Constant Johan, AKKARI Rhalid, MEERPOEL Lieven, Barker Brettell, November 3, 2011: WO/2011/135376 (22 worldwide citation)

The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.